Vesugen (KED)

What is Vesugen?

Vesugen is a synthetic tripeptide — Lys-Glu-Asp (KED) — developed by Professor Vladimir Khavinson as the vascular system bioregulator. It is a Cytogen: the injectable synthetic short-peptide form. Its tissue target is the vascular endothelium — the single-cell-thick lining that coats the interior of every blood vessel in the body.

The endothelium is one of the most active tissues in the body, responsible for regulating blood flow, preventing clot formation, managing inflammation, and maintaining the barrier between blood and vessel wall. Endothelial dysfunction — the progressive failure of this cell layer to perform these functions — precedes and drives atherosclerosis, hypertension, cognitive decline, kidney disease, and erectile dysfunction. It is, in many ways, the common upstream cause of the vascular diseases that kill most people.

Vesugen's proposed role is to maintain endothelial gene expression programs that decline with age — effectively slowing the drift of endothelial cells toward the dysfunctional, pro-inflammatory state that characterizes aged vasculature. It appears in three of the eight protocol stacks on the Bioregulator Series hub because vascular aging is so broadly relevant.

How it works

Endothelial Chromatin Interaction

Consistent with the Khavinson bioregulator model, Vesugen (KED) is proposed to penetrate endothelial cell nuclei and interact with chromatin — regulating gene expression programs in vascular tissue. The tripeptide sequence is derived from research on blood vessel tissue and is proposed to have preferential uptake in endothelial and smooth muscle cells.

Nitric Oxide Pathway Support

Research shows Vesugen upregulates endothelial nitric oxide synthase (eNOS) expression — the enzyme responsible for producing nitric oxide (NO), the primary vasodilatory signal in the vascular system. NO production declines with age and endothelial dysfunction; restoring eNOS activity is one of the most direct interventions for vascular health. This mechanism also underpins Vesugen's reported effects on blood pressure and circulatory function.

Anti-Atherosclerotic and Anti-Inflammatory Effects

Animal studies show Vesugen reduces markers of endothelial inflammation (VCAM-1, ICAM-1 — the adhesion molecules that allow immune cells to stick to vessel walls and initiate plaque formation), reduces oxidative stress in vascular tissue, and attenuates experimentally induced atherosclerotic changes. These are mechanistically important findings for the core pathology of cardiovascular aging.

What the research shows

Community knowledge

Vesugen has high biohacker popularity relative to most organ-specific bioregulators, because vascular aging is universally relevant. It appears routinely in the “Longevity Core” stack alongside Epithalon and Thymalin — the argument being that telomere maintenance (Epithalon) + immune restoration (Thymalin) + vascular health (Vesugen) addresses three of the four most important aging axes simultaneously.

Community protocols typically use 2–3 courses per year at 20–100 mcg/day for 10 days, with higher frequency for people with existing cardiovascular risk factors. Some users pair with Ventfort (the Cytomax equivalent) for complementary broad-spectrum and targeted vascular support. Subjective reports focus on improved circulation, better exercise tolerance, and improved erectile function in men — all consistent with the eNOS/NO mechanism.